Research Library
KPV Peptide Research: Anti-Inflammatory Tripeptide Explained
KPV is the C-terminal tripeptide fragment (lysine–proline–valine) of alpha-melanocyte-stimulating hormone. It retains much of the parent hormone's anti-inflammatory signalling without its pigmentary effects. Research is concentrated in experimental colitis and dermatitis models; human trials are minimal.
Summary
KPV is the C-terminal tripeptide fragment (lysine–proline–valine) of alpha-melanocyte-stimulating hormone. It retains much of the parent hormone's anti-inflammatory signalling without its pigmentary effects. Research is concentrated in experimental colitis and dermatitis models; human trials are minimal.
Last reviewed 2026-09-01
What it is
KPV is a three–amino-acid peptide corresponding to residues 11–13 of alpha-MSH. It is one of the smallest fragments still showing measurable anti-inflammatory activity in models.
Work on alpha-MSH fragments began in the 1980s–1990s once it became clear that the hormone's anti-inflammatory and pigmentary activities could be separated across different regions of the sequence.
A fragment of an endogenous hormone; produced synthetically for research use.
Its size makes it cheap to synthesise and stable, and it can be taken up by intestinal epithelial cells through the PepT1 transporter, which drew interest for inflammatory bowel research.
How it works
In plain terms
KPV appears to quiet the master inflammatory switch inside cells, so damaged tissue produces fewer inflammatory signals.
Technical detail
The dominant reported mechanism is inhibition of NF-κB nuclear translocation and reduced downstream production of IL-6, IL-8 and TNF-α. In intestinal epithelium, uptake occurs via the PepT1 di/tripeptide transporter, giving a direct intracellular route. Melanocortin receptor engagement (MC1R) is reported for the parent hormone but KPV activity appears at least partly receptor-independent.
Pathways involved
- NF-κB nuclear translocation inhibition
- IL-6, IL-8 and TNF-α suppression
- PepT1-mediated intestinal epithelial uptake
- Melanocortin (MC1R) signalling, partial
Current research
Laboratory research
Epithelial and immune cell cultures show dose-dependent reduction in cytokine output after inflammatory challenge.
Animal research
DSS- and TNBS-induced colitis models in mice report reduced histological damage, lower myeloperoxidase activity and improved weight-loss curves. Topical models in dermatitis and wound infection report reduced inflammatory infiltrate.
Human research
Human evidence is limited to small dermatological observations and formulation studies. No adequately powered randomised trial in inflammatory bowel disease has been published.
Ongoing research
Registered activity is sparse; nanoparticle and oral-delivery formulation research is the most active area.
What is being investigated
- Experimental colitis and intestinal inflammation
- Topical dermatitis and skin inflammation
- Cytokine suppression in epithelial cells
- Antimicrobial activity against Candida and S. aureus in vitro
- Oral and nanoparticle delivery to the gut
These are research directions reported in the literature, not established effects or recommendations.
Risks, limitations and unknowns
Read this section before the rest
- No adequately powered human trials in any indication
- Suppressing inflammatory signalling has theoretical infection-risk implications that have not been studied in humans
- Pharmacokinetics of an unmodified tripeptide in humans are poorly characterised
- Product identity and purity vary; a tripeptide is easy to mislabel
- Not an approved medicine in any jurisdiction
Evidence ratings
Laboratory studies
ModerateReproducible cytokine suppression in cell models.
Animal studies
ModerateConsistent colitis-model findings across several groups.
Human studies
NoneNo adequately powered controlled trials published.
Long-term safety
NoneNo chronic exposure data.
Verified peptide suppliers
References
- [1]KPV peptide — indexed literature — PubMed, 1990–present
- [2]KPV and experimental colitis — PubMed, 2008–present
- [3]Alpha-MSH anti-inflammatory fragments — PubMed, 1995–present
- Reference links open searches and records on PubMed and ClinicalTrials.gov so that every statement above can be traced to primary literature.
Frequently asked questions
What is KPV?+
The lysine–proline–valine tripeptide at the C-terminus of alpha-MSH, studied for anti-inflammatory activity.
How does KPV work?+
Principally by inhibiting NF-κB nuclear translocation, reducing IL-6, IL-8 and TNF-α production in epithelial and immune cells.
Is KPV related to melanotan?+
Both derive from alpha-MSH biology, but KPV lacks the pigmentary activity associated with melanocortin agonists such as melanotan peptides.
Is KPV FDA approved?+
No. It is not an approved drug in any major jurisdiction.
Why is KPV studied for gut inflammation?+
Intestinal cells take it up through the PepT1 transporter, so it can act inside the epithelium — attractive for inflammatory bowel models.
Does KPV have antimicrobial activity?+
In-vitro studies report activity against Candida albicans and Staphylococcus aureus, but this has not been demonstrated clinically.
What human research exists on KPV?+
Very little — small dermatological observations and formulation work. No powered randomised trials.
Is KPV the same as BPC-157?+
No. They are unrelated sequences with different proposed mechanisms; KPV targets inflammatory signalling, BPC-157 is studied mainly for angiogenesis.
Continue your research
Independent publication · Research summaries only
Evidence-first
Every claim tied to a study
Cited sources
PubMed · ClinicalTrials.gov
Evidence tiers
Lab, animal and human kept apart
No commerce
Nothing sold or sponsored here
Editorial standards
Reviewed before publication
Research library
Structured compound summaries
Plain language
Mechanisms explained simply
Research use only
Not medical advice